A common hereditary single-nucleotide polymorphism in the gene of FAS and colorectal cancer survival

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 3699-3702

  Hofmann, Guenter ^a   Langsenlehner, Uwe ^b   Langsenlehner, Tanja ^a   Yazdani Biuki, Babak ^a   Clar, Heimo ^a   Gerger, Armin ^a   Fuerst, Florentine ^a   Samonigg, Hellmut ^a   Krippl, Peter ^c   Renner, Wilfried ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Internal Outpatient Department   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Colorectal cancer; FAS; Polymorphism; Survival

Indexed keywords

FAS ANTIGEN;

ARTICLE; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MORTALITY; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIGENS, CD95; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK;

EID: 72449177534     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00720.x     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J. Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55:74-108.
2. Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin. 2008, 58:71-96.
3. O'Brien DI, Nally K, Kelly RG. Targeting the Fas/Fas ligand pathway in cancer. Expert Opin Ther Targets. 2005, 9:1031-44.
4. Peter ME, Budd RC, Desbarats J. The CD95 receptor: apoptosis revisited. Cell. 2007, 129:447-50.
5. Wajant H. CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat Res. 2006, 130:141-65.
6. Abrahams VM, Kamsteeg M, Mor G. The Fas/Fas ligand system and cancer: immune privilege and apoptosis. Mol Biotechnol. 2003, 25:19-30.
7. Ferguson TA, Griffith TS. A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev. 2006, 213:228-38.
8. Kim R, Emi M, Tanabe K. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004, 100:2281-91.
9. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997, 34:577-82.
10. Sibley K, Rollinson S, Allan JM. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003, 63:4327-30.
11. Crew KD, Gammon MD, Terry MB. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis. 2007, 28:2548-51.
12. Zhang B, Sun T, Xue L. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis. 2007, 28:1067-73.
13. Zhang H, Sun XF, Synnerstad I. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J. 2007, 13:233-7.
14. Kang S, Dong SM, Seo SS. FAS-1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet. 2008, 180:1-5.
15. Gaddipati H, Herlyn M. Association of polymorphisms of FAS-1377, FAS-670, and FASL-844 genes with risk factors for cutaneous malignant melanoma. Cancer J. 2007, 13:226-8.
16. Jain M, Kumar S, Lal P. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev. 2007, 31:225-32.
17. Krippl P, Langsenlehner U, Renner W. Re: polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004, 96:1478-9.
18. Lai HC, Sytwu HK, Sun CA. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer. 2003, 103:221-5.
19. Lerma E, Romero M, Gallardo A. Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma. Virchows Arch. 2008, 452:65-74.
20. Li C, Wu W, Liu J. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics. 2006, 16:245-51.
21. Lima L, Morais A, Lobo F. Association between FAS polymorphism and prostate cancer development. Prostate Cancer Prostatic Dis. 2008, 11:94-8.
22. Sun T, Miao X, Zhang X. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004, 96:1030-6.
23. Ueda M, Hung YC, Terai Y. Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol. 2005, 98:129-33.
24. Wang LE, Cheng L, Spitz MR. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer. 2003, 42:1-8.
25. Zhang Z, Wang LE, Sturgis EM. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2006, 12:5596-602.
26. Farre L, Bittencourt AL, Silva-Santos G. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol. 2008, 83:220-2.
27. Gerger A, Hofmann G, Langsenlehner U. Integrin alpha-2 and beta-3 gene polymorphisms and colorectal cancer risk. Int J Colorectal Dis. 2009, 24:159-63.
28. Hofmann G, Langsenlehner U, Renner W. Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk. J Cancer Res Clin Oncol. 2008, 134:591-5.
29. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008, 134:1296-310.
30. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004, 54:295-308.
31. Berger AC, Sigurdson ER, LeVoyer T. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol. 2005, 23:8706-12.
32. Johnson PM, Porter GA, Ricciardi R. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol. 2006, 24:3570-5.
33. Macdonald JS. Adjuvant therapy for colon cancer. CA Cancer J Clin. 1997, 47:243-56.
34. Moertel CG, Fleming TR, Macdonald JS. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990, 322:352-8.
35. Bennett MW, O'Connell J, Houston A. Fas ligand upregulation is an early event in colonic carcinogenesis. J Clin Pathol. 2001, 54:598-604.
36. O'Connell J, Bennett MW, Nally K. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Ann N Y Acad Sci. 2000, 910:178-92.
37. Kanemitsu S, Ihara K, Saifddin A. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol. 2002, 29:1183-8.
38. Kim R, Emi M, Tanabe K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006, 66:5527-36.
39. Matsumoto N, Imamura R, Suda T. Caspase-8- and JNK-dependent AP-1 activation is required for Fas ligand-induced IL-8 production. FEBS J. 2007, 274:2376-84.
40. Engelmark MT, Renkema KY, Gyllensten UB. No evidence of the involvement of the Fas -670 promoter polymorphism in cervical cancer in situ. Int J Cancer. 2004, 112:1084-5.
41. Lai HC, Lin WY, Lin YW. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol. 2005, 99:113-8.
42. Sun T, Zhou Y, Li H. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005, 202:967-74.